Nimotuzumab is a humanized monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR).
The primary endpoint of the trail was PFS (Progression Free Survival) and the secondary endpoints included safety, ORR (Overall Response Rate), OS (Overall Survival), and PK.
The results of the trial suggested that overall survival was 293.0 days in the N+I arm compared with 227.0 days in the I arm among 82 patients.
The median PFS was 73.0 days in the N+I arm compared with 85.0 days in the I arm.
YM BioSciences president and CEO Nick Glover said the overall findings of the study are positive, and support the promise of Nimotuzumab in this important global cancer market.
"Although not powered for statistical significance, in subgroup analyses these data demonstrated that EGFR-positive patients treated with Nimotuzumab showed a potential improvement of Progression Free Survival and Overall Survival in gastric cancer," Glover said.
"This is consistent with evidence that nimotuzumab selectively targets tissues over-expressing EGFR."